Forte Biosciences, Inc. (FBRX)
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement
Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.
Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet
Forte Biosciences (FBRX) offers upside as FB102 demonstrates efficacy in both celiac disease and vitiligo, suggesting platform potential beyond a single indication. FB102's mechanism targets CD122, modulating key immune pathways, with placebo-controlled data showing 21.7% F-VASI benefit in vitiligo and histologic protection in celiac disease. FBRX holds a pro forma cash position of ~$220M post-financing, providing 11–12 quarters of runway to advance Phase II/III trials across multiple autoimmune indications.
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
Forte Biosciences shares surge after positive phase 1b vitiligo results
Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b clinical trial results for FB102, an investigational therapy for vitiligo, showing statistically significant improvements in disease severity compared with placebo. Vitiligo is a chronic autoimmune disorder where the immune system destroys melanocytes, the pigment-producing cells responsible for skin color, resulting in distinct white patches on the skin, hair, or mucous membranes.
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts
Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically significant Phase 1b efficacy in Celiac disease, positioning FBRX as a potential frontrunner for first drug approval in this indication. Upcoming Phase 1b data in vitiligo and alopecia areata, both large and competitive markets, represent major catalysts for FBRX in 2024.
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
